ArticleFrontiers in cell and developmental biology2022
Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients.
Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- The relevance of membrane lipid composition in exosome-based precision dermatology.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Integrating mass spectrometry-based multi-omic signatures of extracellular vesicles: from discovery to clinical translation.Clinical & translational immunology · 2026Review
- Exploring Lipid Metabolic Reprogramming: Mechanistic Insights and Implications for Tumor Radiotherapy.International journal of biological sciences · 2026Review
- Evaluating Novel Direct Injection Liquid Chromatography-Mass Spectrometry Method and Extraction-Based Workflows for Untargeted Lipidomics of Extracellular Vesicles.Journal of proteome research · 2025Article
- The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects.International journal of molecular sciences · 2025Review
- Roles for Exosomes in the Pathogenesis, Drug Delivery and Therapy of Psoriasis.Pharmaceutics · 2025Review
- The Potential Application of Exosomes as Therapeutic Agents, Carriers, and Biomarkers in Skin Diseases.International journal of nanomedicine · 2025Review
- miRNAs and exosomes in psoriasis: coordinating cytoskeleton dynamics and extracellular matrix remodeling.Frontiers in cell and developmental biology · 2025Review
- The Role of Extracellular Vesicles in the Development and Treatment of Psoriasis: Narrative Review.Pharmaceutics · 2024Review
- Size matters: Biomolecular compositions of small and large extracellular vesicles in the urine of glioblastoma patients.Journal of extracellular biology · 2024Article
- Extracellular vescicles in psoriasis: from pathogenesis to possible roles in therapy.Frontiers in immunology · 2024Review
- Synovial fluid extracellular vesicles as arthritis biomarkers: the added value of lipid-profiling and integrated omics.Extracellular vesicles and circulating nucleic acids · 2024Review
- Exosomes: The emerging mechanisms and potential clinical applications in dermatology.International journal of biological sciences · 2024Review
- Decreased in n-3 DHA enriched triacylglycerol in small extracellular vesicles of diabetic patients with cardiac dysfunction.Journal of diabetes · 2023Article
- Extracellular Vesicles Contribute to the Difference in Lipid Composition between Ovarian Follicles of Different Size Revealed by Mass Spectrometry Imaging.Metabolites · 2023Article
- Phosphatidylglycerol to Treat Chronic Skin Wounds in Diabetes.Pharmaceutics · 2023Review
- Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023Review
- Extracellular Vesicles as New Players in Drug Delivery: A Focus on Red Blood Cells-Derived EVs.Pharmaceutics · 2023Review
- Article
- Plasma Levels of Interleukins 36α, 36β, and 37 in Patients with Psoriasis and Their Correlation with Disease Activity Parameters.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disorder affecting children and adults. To date no approved biomarkers for diagnosis of this disease and follow up of patients have been translated into clinical practice. Recently, extracellular vesicles (EVs) secreted by all cells and present in almost all biological fluids are playing a crucial role in diagnosis and follow up of several diseases, including psoriasis. Since many psoriatic patients show altered plasma lipid profiles and since EVs have been involved in psoriasis pathogenesis, we studied the phospholipid profile of EVs, both microvesicles (MV) or exosomes (Exo), derived from plasma of psoriatic patients undergoing systemic biological treatment (secukinumab, ustekinumab, adalimumab), in comparison with EVs of untreated patients and healthy donors (HD). EVs were evaluated by immune electronmicroscopy for their morphology and by NanoSight for their amount and dimensions. EV phospholipid profiling was performed by High Resolution Liquid Chromatography-Mass Spectrometry and statistical Partial Least Squares Discriminant Analysis. Our results demonstrated that psoriatic patients showed a higher concentration of both MV and Exo in comparison to EVs from HD. The phospholipid profile of Exo from psoriatic patients showed increased levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol and lysoPC compared to Exo from HD. Sphingomyelin (SM) and phosphatidylinositol (PI) are the only phospholipid classes whose levels changed in MV. Moreover, the therapy with ustekinumab seemed to revert the PE and PC lipid composition of circulating Exo towards that of HD and it is the only one of the three biological drugs that did not alter SM expression in MV. Therefore, the determination of lipid alterations of circulating EVs could harbor useful information for the diagnosis and drug response in psoriatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.